Clinical study on the efficacy and safety of EstroG-100J for menopausal symptoms: randomized double-blinded controlled study

INTERVENTION: EstroG‐100J Placebo CONDITION: Menopausal symptoms PRIMARY OUTCOME: Difference of the mean change of Kupperman's menopausal index (KMI) (from week 0 to 8) between placebo and EstroG‐100J groups INCLUSION CRITERIA: 1) Subjects with abilities to present consent who have been informed of the objectives and the contents of the present clinical trial, have sufficiently understood them, and have voluntarily expressed the consent by written documents. 2) Japanese adult females with pre‐, peri‐ and post‐menopausal symptoms. 3) Females with Kupperman's menopausal index (KMI) of not lower than 20.